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Background: The major disadvantage of rocuronium is the withdrawal movement associated with its injection. The 
analgesic effect of perioperative gabapentin has been evaluated. We investigated the effects of gabapentin on the 
withdrawal movement induced by rocuronium injection.
Methods: 86 ASA physical status I or II patients, aged 18-69 years who were scheduled to undergo elective surgery 
with general anesthesia were enrolled. Patients were randomly allocated into two groups to receive either gabapentin 
600 mg or placebo 2 hours prior to surgery. The patient’s response to rocuronium injection was graded using a 
4-point scale.
Results: The incidence of withdrawal movement after rocuronium administration was significantly lower in the 
gabapentin group (55.0% in the control group vs 28.6% in the gabapentin group). The number of patients with 
generalized response indicating severe pain, was 9 (22.5%) in the control group and 3 (7.1%) in the gabapentin group.
Conclusions: Pretreatment with a single oral dose of gabapentin 600 mg reduced the incidence and severity of 
withdrawal movement after rocuronium administration. (Korean J Anesthesiol 2011; 61: 367-371)
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Introduction
Rocuronium is a commonly used steroidal non-depolarizing 
neuromuscular blocking agent with a rapid onset of action and 
an intermediate duration [1]. However, even in unconscious 
patients during anesthetic induction, rocuronium causes with-
drawal movement of the injected hand or arm, or generalized 
movements of the body after intravenous injection. The major 
disadvantage of rocuronium is the pain associated with its 
injection, and generalized movements of the body caused by 
injection pain may even lead to reflux of gastric contents and 
pulmonary aspiration [2]. A number of treatment modalities 
have been recommended in an attempt to reduce withdrawal 
responses, such as priming technique, local warming at the 
injection site, pretreatment or mixing with ondansetron, 
lidocaine, tramadol, fentanyl, magnesium sulphate, sodium 
bicarbonate, alfentanil and antihistamine [3-8].
Gabapentin is a structural analogue of γ-amino butyric acid 
(GABA) and was initially introduced as an antiepileptic drug. 
The drug has also demonstrated antinociceptive, analgesic, 
and antihyperalgesic properties. Recently it has been used 
to treat acute and chronic pain after surgery, and to reduce 
postoperative opioid requirement [9-13]. 
To our knowledge, a limited number of studies have evaluated 
the potential influence of gabapentin in general anesthetic 
induction with rocuronium. This double-blind, randomized, 
placebo-controlled study aimed to investigate the effects 
of gabapentin on the incidence and severity of rocuronium 
injection pain and the changes in hemodynamic variables 
during anesthetic induction.
Materials and Methods
After obtaining approval from the institutional ethics com-
mittee and patients’ written informed consent, 86 ASA physical 
status I or II patients, aged 18-69 years who were scheduled 
to undergo elective surgery with general anesthesia were 
enrolled. Exclusion criteria were as follows: patients with ASA 
physical status III or greater, neurological deficits, pregnancy, 
anticipated difficult airway, body weight more than 20% of ideal 
body weight, substance abuse, alcoholism, and those receiving 
analgesics, sedatives, hypnotics, antidepressants, hemodynamic 
instabilities during induction. Four patients were dropped from 
the study. Patients were randomly allocated into 2 groups (43 
in each group) with the help of a computer generated table of 
random numbers to receive either gabapentin 600 mg (Group G) 
or placebo (Group C) 2 hours prior to surgery. 
None of the patients were premedicated, and standard 
monitoring with electrocardiogram, non-invasive blood 
pressure, and pulse oximetry was performed. Blood pressure 
was measured at 1-min intervals. An 18-G intravenous cannula 
was placed preoperatively in the vein on the dorsum of the 
hand in the ward and infusion of lactated Ringer’s solution 
was started. Side effects of gabapentin including sedation, 
nausea, vomiting, somnolence, lightheadedness, dizziness, 
headache and visual disturbances were recorded before 
induction. If necessary, symptoms were treated. After 3 min 
of preoxygenation, 2.5% thiopental sodium 5 mg/kg was 
injected. When the verbal response and the eyelash reflex were 
abolished, an intubating dose of rocuronium 0.6 mg/kg was 
injected over 5 seconds and intravenous fluid was continously 
administered for 10 seconds. While rocuronium was being 
injected, withdrawal movement was graded as follows: grade 
0 = no response, grade 1 = movement/withdrawal at the wrist 
only, grade 2 = movement/withdrawal involving the arm only 
(elbow/shoulder), and grade 3 = generalized response with 
movement/withdrawal in more than one extremity, cough, or 
breath-holding [14]. Mean blood pressure (MBP) and heart 
rate (HR) were recorded before the induction, 1 min before 
intubation, 1 min and 5 min after intubation.
With reference to the previous study [15,16], the incidence 
of withdrawal movements was predicted to be approximately 
60%, and a 50% reduction in incidence to 30% was considered 
to be clinically relevant. Power analysis showed that 82 patients 
were needed for 80% power (β = 0.2) and 95% significance level 
(α = 0.05) to detect 50% reduction in incidence. 43 patients 
were enrolled per group assuming a 5% dropout rate. Statistical 
analyses were performed using SPSS 14.0 for Windows 
(Statistical Package for Social Science, SPSS Inc, Chicago, IL, 
USA). Data are expressed as mean ± standard deviation (SD) 
or numbers (percentages). Discrete variables such as gender, 
ASA, the incidence of withdrawal movement were analyzed 
using Chi-square or Fisher’s exact test. Student’s t-test or Mann-
Whitney test were used to compare continuous variables such 
as age, weight, height, mean blood pressure (MBP) and heart 
rate (HR) between groups. ANOVA for repeated measures was 
used to compare the changes in mean hemodynamic variables 
within the group. A P value of less than 0.05 was considered 
statistically significant. 
Results
Both groups were comparable with respect to age, gender, 
ASA status, weight, and height (Table 1). None of the patients 
in Group G showed gabapentin-related side effects such as 
sedation, nausea, vomiting, somnolence, lightheadedness, 
dizziness, headache and visual disturbances before anesthetic 
induction. The overall incidence (Grade 1-3) of withdrawal 
movement after rocuronium administration was significantly 
different between both the groups (55.0% in the Group C vs 369 www.ekja.org
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28.6% in the Group G, P = 0.02). The number of patients with 
grade 3 withdrawal response, indicating severe pain, was 9 
(22.5%) and 3 (7.1%) in Group C, and Group G, respectively (P < 
0.05, Table 2). 
Baseline hemodynamic variables were similar between the 
two groups (Table 3). HR and MBP at 1 min before intubation 
were significantly lower in Group G compared with Group C. 
However, HR and MBP at 1 and 5 min after intubation were 
comparable between the two groups. Comparison of HR and 
MBP within each group showed significant differences among 
values with the course of time. 
Discussion
The present study demonstrated that pretreatment with 
a single dose of gabapentin 600 mg 2 hours before surgery 
significantly reduced the incidence and the severity of with-
drawal movement induced by rocuronium administration. 
Moreover, HR and MBP at 1-min before tracheal intubation 
were lower in patients pretreated with gabapentin. 
The incidence of withdrawal movement associated with 
rocuronium injection has been reported in 50-100% of patients 
[15-18]. In our study, the incidence of withdrawal response was 
55.0% in the control group. Compared with the previous study, 
the occurrence of withdrawal movement was comparatively 
lower in our study. Age and gender play important roles in 
rocuronium-induced withdrawal movements [19-22]. The 
overall incidence of rocuronium-induced pain was lower in 
older patients aged over 65 years compared with that in the 
young patients aged between 20-40 years in the placebo 
group [19]. Gender difference in severity and incidence of 
rocuronium-induced pain also exists in adults [21]. A previous 
study has suggested that females reported more frequent and 
severe pain responses than males. Females are considered to be 
20-25% more sensitive to rocuronium than males [22]. In our 
study, mean age of patients in the control group was 58.9 ± 8.3 
years and the ratio of females to males was 35%. The relatively 
low incidence of rocuronium-induced pain may be related with 
patients’ characteristics such as older age and male dominance. 
Gabapentin is an antiepileptic drug and a structural analogue 
of γ-amino butyric acid (GABA). It has been proved to be 
effective in controlling acute postoperative pain and reducing 
postoperative opioid requirement [9-13]. In addition, pretreat-
ment with gabapentin attenuated the pressor response to 
laryngoscopy and tracheal intubation [23]. Gabapentin is not 
metabolized in humans and its elimination is dependent on 
renal clearance. The elimination half-life of gabapentin is 5 to 7 
hours after an oral dose of 200 to 400 mg. After a single dose of 
300 mg, maximum plasma concentration is reached in about 
2-3 hours. The bioavailability of a 600 mg single oral dose of 
gabapentin is about 40% and decreases with an increasing dose. 
Single dose of 600 mg administered 2 hours before surgery 
Table 1. Patient Demographic Characteristics
Group C (n = 40) Group G (n = 42)
Age (yr)
Gender (M/F)
ASA (I/II)
Weight (kg)
Height (cm)
58.9 ± 8.3
26/14
10/30
64.9 ± 9.9
163.2 ± 9.2
60.0 ± 5.2
28/14
11/31
63.8 ± 8.2
162.5 ± 9.2
Values are mean ± SD or numbers. Group C: control group, Group G: 
gabapentin group.
Table 2. Incidence and Severity of Withdrawal Movement
Group C (n = 40) Group G (n = 42)
Grade 0
Grade 1
Grade 2
Grade 3
18 (45.0%)
3 (7.5%)
10 (25.0%)
9 (22.5%)
30 (71.4%)*
0 (0%)
9 (21.4%)
3 (7.1%)*
Values are presented as number of patients. Group C: control group, 
Group G: gabapentin group. Grade 0: no movement, Grade 1: move-
mentat the wrist only, Grade 2: movement involving upper arm and 
shoulder, Grade 3: generalized movement. *P < 0.05 compared with 
group C.
Table 3. Hemodynamic Changes
Group C (n = 40) Group G (n = 42)
HR (BPM) MBP (mmHg) HR (BPM) MBP (mmHg)
Baseline
Pre-1m
Post-1m
Post-5m
74.1 ± 10.9
§
82.7 ± 11.8
§
97.8 ± 13.6
† , ‡ , ∥
81.4 ± 14.6
§
93.8 ± 11.4
§
89.8 ± 11.8
§
109.2 ± 17.1
† , ‡ , ∥
88.9 ± 10.6
§
73.5 ± 12.8
§
75.4 ±13.1*, §
95.1 ± 18.8
† , ‡ , ∥
79.4 ± 14.2
§
92.7 ± 10.7
‡ , §
81.2 ± 12.2*, † , § , ∥
113.7 ± 15.9
† , ‡ , ∥
91.5 ± 10.2
‡ , §
Values are mean ± SD. Group C: control group, Group G: gabapentin group. Baseline: before induction, Pre-1m: 1 min before intubation, Post-
1m: 1 min after intubation, Post-5m: 5 min after intubation, *P < 0.05 compared with group C, 
†P < 0.05 compared with baseline value within 
the group, 
‡P < 0.05 compared with Pre-1m within the group, 
§P < 0.05 compared with Post-3m within the group, 
∥P < 0.05 compared with 
Post-5m within the group.    370 www.ekja.org
Vol. 61, No. 5, November 2011 Gabapentin for rocuronium injection
is within the recommended dose limits of 300 to 1200 mg, 3 
times a day [24]. It seems to be clinically impractical to use oral 
gabapentin with a delayed onset of action and a long half-life, 
for preventing temporary withdrawal movement. However, 
since patients who were treated with gabapentin before surgery 
benefited from its influence on maintaining the hemodynamic 
stability after tracheal intubation and postoperative analgesic 
effect, pretreatment with oral gabapentin deserves consideration. 
Gabapentin is also regarded as a safe drug. It has fewer 
side-effects and minor interactions with other drugs. Older 
patients occasionally show increased sensitivity to drugs and 
doses of gabapentin may be adjusted to their age. We did not 
observe any adverse effects associated with a dose of 600 mg of 
gabapentin and it was well tolerated.
Although the exact mechanism of action of gabapentin is 
unknown, proposed mechanisms are as follows: its ability to 
increase the concentration and the rate of GABA synthesis 
in the brain; bind with high affinity to binding sites in brain 
tissues that are associated with auxiliary subunit of voltage-
sensitive calcium channel (α2δ subunits); reduce the release 
of monoamine neurotransmitters; inhibit voltage-activated 
sodium channels; and increase serotonin concentration in 
human blood [25,26]. The drug inhibits voltage-gated calcium 
channels in the membrane and acts in a similar way to calcium 
channel blockers [27]. Calcium channel blockers have shown 
antinociceptive effects in animals [28]. Miranda et al. suggested 
that a substance with a calcium channel blocking effect should 
probably have some antinociceptive properties. We speculated 
that the calcium channel blocking property of gabapentin might 
also have alleviated HR and MBP before tracheal intubation in 
the gabapentin group.
In conclusion, pretreatment with a single oral dose of 600 mg 
gabapentin attenuated the incidence and severity of withdrawal 
movement after rocuronium administration. The dose used 
in this trial well tolerated and the patients did not manifest 
any side effects. Further studies may be needed to investigate 
the appropriate dose of gabapentin and compare gabapentin 
with other treatment modalities for preventing withdrawal 
movement related to rocuronium injection.
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